Japanese
 NBRP Rat No: 0668 Strain Name: F344-Sv2am1Kyo Commmon Name: 
 Principal Investigator  Tadao Serikawa
 Organization   Graduate School of Medicine, Kyoto University Institute of Laboratory Animals
 Address  Yoshidakonoe-cho, Sakyo-ku

606-8501 Kyoto

  JAPAN
 Telephone  075-753-4360  Fax:  075-753-4409  serikawa@anim.med.kyoto-u.ac.jp
 Inbred Generations    
   
 Coat Color
 Deposition Status
 
 albino (c)
  Embryo      Sperm      Live Animals
 Usage Restrictions  The recipient of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the DEPOSITOR.
For a commercial use of this resource, a new contract must be concluded between the depositor and the recipient. 
 Genetic Status   Inbred   Segregating   Congenic   Consomic    Recombinant 
  Coisogenic   Spont. Mutant    Transgene   Ind. Mutant    Others 
 Comercial Availability   
 Research Category   Diabetes Obesity    Neurobiology    Ophthalmology    Dentistry    Cardio- Hypertension 
  Oncology   Metabolism   Otorhinology    Immunology    Infectious Disease
  Osteology    Internal Medicine   Dermatology   Reproduction    Development
  Behavior    Hematology    Urology   Pharmacology   Others 
  Control Strains   Reporter gene Strains  
 Gene Sv2a : synaptic vesicle glycoprotein 2a
 Origin Established by ENU mutagenesis (gene-driven). This strain has misssense mutation （L174Q）in Sv2a gene. 
 Strain Characteristics Sv2aL174Q（F344-Sv2am1Kyo） is a novel rat model carrying the missense mutation (L174Q) in the Sv2a gene encoding the synaptic vesicle glycoprotein 2A. Sv2aL174Q rats show normal appearance and grow well, however, they are sensitive to seizure induction by pentylenetetrazole (PTZ, GABAA antagonist). Sv2aL174Q rats are also very susceptible to the kindling development induced by repeated treatment with PTZ or electrical stimulation of the amygdala. Neurochemical studies reveal that depolarization-evoked synaptic GABA release is impaired in the hippocampus and amygdala of Sv2aL174Q rats.  
 Breeding Conditions Good breeding performance 
 Genotyping  
 References  Ohno Y, Tokudome K
Therapeutic role of synaptic vesicle glycoprotein 2A (SV2A) in modulating epileptogenesis.
CNS Neurol. Disord. Drug Targets, 16:463-471, 2017

Tokudome K, Okumura T, Terada R, Shimizu S, Kunisawa N, Mashimo T, Serikawa T, Sasa M, Ohno Y.
A Missense Mutation of the Gene Encoding Synaptic Vesicle Glycoprotein 2A (SV2A) Confers Seizure Susceptibility by Disrupting Amygdalar Synaptic GABA Release.
Front Pharmacol. 2016 Jul 14;7:210.

Tokudome K, Okumura T, Shimizu S, Mashimo T, Takizawa A, Serikawa T, Terada R, Ishihara S, Kunisawa N, Sasa M, Ohno Y.
Synaptic vesicle glycoprotein 2A (SV2A) regulates kindling epileptogenesis via GABAergic neurotransmission.
Sci Rep. 2016 Jun 6;6:27420.